

INDEX

(January-December 1965)

A

- Abdomen, clinical effects of irradiation, *Feb.*, 30
- Acanthosis nigricans, in lung cancer, *July*, 23 f.
- Acidosis
diabetic, *Sept.*, 32 ff.
magnesium loss in, *May*, 26
management, *Sept.*, 34 ff.
metabolic, in uremia, *Oct.*, 41 f.
- ACTH
in acute allergic reaction, *June*, 10
allergic reactions to, *June*, 31
deficiency, effect on adrenal, *Mar.*, 22 ff.
effect on cortisol secretion, *Mar.*, 7
response tests
in adrenal insufficiency, *Mar.*, 28 f., 46
in lung cancer, *July*, 15
secretion in Cushing's syndrome, *Mar.*, 31 f.
- Acupuncture, in congestive failure, *Dec.*, 42
- Adenosinetriphosphatase, activation by magnesium, *May*, 12
- Addison's disease, *Mar.*, 20 ff.
tests for, *Mar.*, 27, 28 f., 46, 47
- Adenoma
adrenal, Cushing's syndrome with, *Mar.*, 33, 46
bronchial
ACTH activity from, *Mar.*, 32
carcinoid, *July*, 19 f.
pituitary, *Feb.*, 47
- Adipose tissue
fat utilization in, *Sept.*, 12
function in fasting, *Sept.*, 5 f.
insulin effects in, *Sept.*, 11 f.
- Adolescence, early: with virilization, *Mar.*, 38 f.
- Adrenal gland
hyperactivity
drugs to suppress, *July*, 16
in lung cancer, *July*, 13 ff.
hyperplasia
congenital, *Mar.*, 37 ff., 44 ff.
in Cushing's syndrome, *Mar.*, 31 f., 36
insufficiency, *Mar.*, 20 ff.
acute, *Mar.*, 25 f.
- in lung cancer, *July*, 17
pituitary, *Mar.*, 22 ff.
tests for, *Mar.*, 26 ff., 46, 47
processes destroying, *Mar.*, 20 f.
tumors
causing Cushing's syndrome, *Mar.*, 33, 46
radiologic technics in, *Mar.*, 37
- Adrenogenital syndrome, *Mar.*, 43 ff., 46
- Afibrinogenemia, congenital, *Nov.*, 28, 34
- Agglutination tests, in allergic drug reactions, *June*, 20, 21
- Alcoholism
chronic
magnesium deficit in, *May*, 25
folate deficiency in, *Aug.*, 15, 18
as health problem, *Jan.*, 4 ff.
mortality, *Jan.*, 17 f.
patterns of drinking, *Jan.*, 5 f.
physical complications, *Jan.*, 12 ff.
theory of addiction, *Jan.*, 5
treatment, *Jan.*, 11 ff.
disulfiram in, *Jan.*, 27 f.
during sobriety, *Jan.*, 26 f.
pharmacologic, *Jan.*, 20 ff., 29 ff.
physician's role, *Jan.*, 18 f.
- Aldosterone
antagonists, in congestive failure, *Dec.*, 40 f.
secretion
and control, *Mar.*, 8
and 21-hydroxylase deficiency, *Mar.*, 41
in lung cancer, *July*, 15
structure, *Mar.*, 5
- Aldosteronism, magnesium deficit in, *May*, 26
- Alkalosis
hypochloremic, due to mercurials, *Dec.*, 40
hypokalemic, in lung cancer, *July*, 14
- Allergy, *see* Hypersensitivity reactions
- Alpha methyl-dopa, for carcinoid syndrome, *July*, 20
- Amino acids, insulin role in transport, *Sept.*, 11
- Aminophylline
for allergic reaction, *June*, 9
with mercurial diuretic, *Dec.*, 40

- Aminopyrine, allergy to, *June*, 33 f.
 Amitriptyline, for depression of alcoholic, *Jan.*, 24, 26
 Amyloidosis, renal, *Oct.*, 31
 Analgesics, allergy to, *June*, 31 ff.
 Anaphylaxis, *June*, 5 f.
 in desensitization, *June*, 41 f.
 management, *June*, 9 f.
 penicillin, *June*, 24 f.
 conjugate for skin testing, *June*, 25 ff.
 sources of reactions, *June*, 7 f.
 bee sting, *June*, 39 f.
 biologic products, *June*, 31
 penicillin, *June*, 24 f.
 Androgens, adrenal secretion of, *Mar.*, 9 f.
 Androsterone, adrenal secretion of, *Mar.*, 9
 Anemia
 allergic mechanisms in, *June*, 20
 in lung cancer, *July*, 29
 megaloblastic
 biochemical mechanisms, *Aug.*, 4 f.
 clinical picture, *Aug.*, 14
 differential diagnosis, *Aug.*, 14 f.
 etiologic classification, *Aug.*, 15 ff.
 immediate therapy, *Aug.*, 31 ff.
 maintenance therapy, *Aug.*, 33 ff.
 morphologic signs, *Aug.*, 7 ff.
 neurologic damage, *Aug.*, 18 f.
 pernicious, *Aug.*, 16
 antibody to intrinsic factor in, *Aug.*, 29 f.
 gastric analysis in, *Aug.*, 26 f.
 relation to heart failure, *Dec.*, 19 f.
 "shotgun" preparations for, *Aug.*, 35
 Anesthetics, local: reactions to, *June*, 34
 Aneuploid, defined, *April*, 15
 Angiitis, hypersensitivity, *Oct.*, 27, 34
 Angina pectoris, digitalis in, *Dec.*, 36
 Antibiotics
 causing clotting defect, *Nov.*, 30
 in glomerulopathies, *Oct.*, 36
 Antibody
 circulating, to intrinsic factor, *Aug.*, 29 f.
 reaginic, in immediate reaction, *June*, 8
 Anticoagulants
 activity, measurement in plasma, *Nov.*, 15, 24 f.
 circulating
 assays for, *Nov.*, 24 f.
 inhibiting clotting, *Nov.*, 35 f., 41, 49
 coumarin, effect on vitamin K, *Nov.*, 31
 in heart failure
 during bedrest, *Dec.*, 22
 prophylactic, *Dec.*, 19
 Antidepressants, for "dry" alcoholic, *Jan.*, 25 f., 31
 Antidiuretic hormone, excretion in lung cancer, *July*, 17 ff.
 Antigens
 in anaphylactic reactions, *June*, 7 f.
 in contact dermatitis, *June*, 16
 Antihemophilic factor
 anticoagulant inhibiting, *Nov.*, 35 f., 49
 assay of, *Nov.*, 23, 25
 deficiency, *Nov.*, 25, 27, 29, 49
 in thrombin formation, *Nov.*, 7
 Antihistamines
 for allergic reaction, *June*, 9 f.
 in serum sickness, *June*, 13
 topical, causing dermatitis, *June*, 37
 Antihypertensive agents, in glomerulopathies, *Oct.*, 35
 Antiplasmins, *Nov.*, 13
 Antitoxins, reactions to, *June*, 29 f.
 Anxiety
 in addiction to alcohol, *Jan.*, 8 f.
 relief, with phenothiazines, *Jan.*, 22, 25
 Aorta, coarctation of, *Dec.*, 17
 Apamide, *June*, 33
 Arterenol, for anaphylactic shock, *June*, 9
 Arrhythmias
 digitalis-induced, *Dec.*, 29 f.
 heart failure with, *Dec.*, 20
 Arthus phenomenon, *June*, 21
 Ascites, in congestive failure, *Dec.*, 41 f.
 Aspirin
 allergy to, *June*, 31 ff.

Aspirin (*cont.*)
 nonallergic substitute for, *June*, 33
 skin tests with, *June*, 33
 Asthma
 acute, from aspirin, *June*, 32 f.
 in anaphylaxis, *June*, 6 f.
 management, *June*, 9
 corticosteroids and allergy in, *June*, 10
 miscellaneous drugs causing, *June*, 37
 Ataraxics, in alcoholism, *Jan.*, 21 ff., 30
 Atomic particles, *Feb.*, 11
 Atrophy, adrenal, *Mar.*, 21, 22
 Autoimmune processes, adrenal necrosis from, *Mar.*, 21
 Autosomes, congenital abnormalities, *April*, 17 ff.
 Azathioprine, in glomerulopathies, *Oct.*, 34 f.

B

Bacteria, in B₁₂ and folate deficiency, *Aug.*, 16, 17
 Barr body, *April*, 8, 10
 Bed rest
 in acute glomerulitides, *Oct.*, 35 f.
 in congestive failure, *Dec.*, 20 f.
 Benzodiazepine derivatives, in alcoholism, *Jan.*, 24 f., 31
 Beriberi, congestive failure, in, *Dec.*, 16 f.
 Betatron, *Feb.*, 15, 17
 Bladder carcinoma, radiation therapy, *Feb.*, 32 f.
 Bleeding time, causes of prolonged, *Nov.*, 15
 Blood
 fibrinolysis of clotted, *Nov.*, 13
 hypersensitivity reactions affecting, *June*, 19 ff.
 peripheral, in diagnosis of megaloblastic anemia, *Aug.*, 10 ff.
 Blood clotting disorders
 acquired, *Nov.*, 29 ff.
 hereditary, *Nov.*, 25 ff.
 laboratory diagnosis, *Nov.*, 14 ff.
 factors, *Nov.*, 6 ff.
 assays for, *Nov.*, 22 ff.

vitamin K-dependent, *Nov.*, 29 f., 44 f.
 mechanism, *Nov.*, 3 ff.
 normal inhibitors, *Nov.*, 11 f.
 time, *Nov.*, 14
 measurement, *Nov.*, 15 ff.
 prolonged, *Nov.*, 41 f.
 Blood pressure
 glomerular capillary, *Oct.*, 6 f.
 venous, in right heart failure, *Dec.*, 12
 Blood transfusion: packed cell, in severe anemia, *Aug.*, 31 f.
 Blood vessel injuries, platelets in repair, *Nov.*, 10
 Bone marrow
 metaphases from, *April*, 5 f.
 orthochromatic megaloblasts in, *Aug.*, 8 f.
 Brain syndrome, in alcoholics, *Jan.*, 17
 Breast carcinoma, radiotherapy, *Feb.*, 45 f.

C

Calcium
 in blood clotting, *Nov.*, 5, 8
 excess, in lung cancer, *July*, 20 f.
 levels, in magnesium deficit, *May*, 8 ff.
 therapy, in magnesium excess, *May*, 28 f.
 Cancer
 diagnosis and clinical evaluation, *Feb.*, 6 ff.
 radiotherapy, *Feb.*, 20 ff.
 with chemotherapy, *Feb.*, 51 f.
 clinical response, *Feb.*, 29 ff.
 with surgery, *Feb.*, 35, 45, 51 f.
 staging of disease, *Feb.*, 8
 therapy, choice of modality, *Feb.*, 8 f.
see also Carcinoma
 Carbohydrate metabolism, in uncontrolled diabetes, *Sept.*, 31
 Carbonic anhydrase inhibitors, in heart failure, *Dec.*, 40
 Carcinoid syndrome, in bronchial adenoma, *July*, 19 f.
 Carcinoma
 acanthosis nigricans with, *July*, 23 f.

- adrenal, Cushing's syndrome in, *Mar.*, 33, 46
- gastric, with pernicious anemia, *Aug.*, 36
- of lung, *see* Lung carcinoma
- neuromyopathic abnormalities with, *July*, 25 ff.
- results of radiotherapy, *Feb.*, 31 ff.
- vascular abnormalities in, *July*, 28 ff.
- Cation exchange resins, in heart failure, *Dec.*, 41
- Centromere, *April*, 8
- position in chromosome, *April*, 8, 12 f.
- Cerebellum, cortical degeneration, with lung cancer, *July*, 25 f.
- Cervix carcinoma
- metastatic survey in, *Feb.*, 7
- radiation therapy, *Feb.*, 21 f., 31 f.
- Cesium-137, *Feb.*, 12
- Chemicals
- causing chromosomal aberrations, *April*, 36 f.
- causing contact dermatitis, *June*, 17
- Chemotherapy
- in bronchogenic cancer, *July*, 6
- in prophylaxis of congestive failure, *Dec.*, 43
- with radiotherapy, in cancer, *Feb.*, 51 f.
- Chloramphenicol, reactions to, *June*, 20, 28
- Christmas disease, *Nov.*, 7, 40
- symptoms, *Nov.*, 28
- transmission, *Nov.*, 25 f.
- Christmas factor
- assay of, *Nov.*, 23
- in thrombin formation, *Nov.*, 7
- Chromatids, *April*, 8
- Chromatin, sex, *April*, 8, 10, 25
- Ch¹ chromosome, *April*, 42 f.
- Chromosomes
- abnormalities, *April*, 15 ff.
- acquired, *April*, 35 ff.
- congenital, *April*, 17 ff.
- definitions, *April*, 15 f.
- centromere position in, *April*, 8, 12 f.
- Ch¹, *April*, 42 f.
- chemical components, *April*, 3
- deletion, *April*, 15
- fusion, *April*, 15
- Chromosome number
- modal, *April*, 10
- monosomic, *April*, 16, 19
- normal karyotypes, *April*, 12 ff.
- number
- and congenital abnormalities, *April*, 17 ff.
- human somatic, *April*, 4 f.
- in leukemia, *April*, 38
- in mongolism, *April*, 17, 19
- in neoplasia, *April*, 45
- patterns
- abnormal, *April*, 15 ff., 17 ff.
- in leukemia, *April*, 37 ff., 42 ff.
- see also* Sex chromosome patterns
- Philadelphia (Ph¹), *April*, 39 ff.
- satellite, *April*, 11
- sex, *see* X chromosome, Y chromosome
- staining quality of, *April*, 9 f.
- synonymy of, *April*, 12 f.
- translocation of, *April*, 15, 17, 19
- trisomy, *April*, 16, 17, 19 f., 22 f., 25
- Circulation time, in congestive failure, *Dec.*, 12
- Cirrhosis, magnesium deficit in, *May*, 26
- Clubbing, digital: with pulmonary hypertrophic osteoarthopathy, *July*, 19, 22 f.
- Coagulation, *see* Blood clotting
- Coarctation of aorta, recognition of, *Dec.*, 17
- Cobalt-60
- radiations from, *Feb.*, 12
- teletherapy units, *Feb.*, 13, 15
- Cocaine derivatives, reactions to, *June*, 34
- Cold hypersensitivity, *June*, 14
- Coma, diabetic, *Sept.*, 29 ff., 33
- management, *Sept.*, 32
- Combined system disease, in vitamin B₁₂ deficiency, *Aug.*, 19
- Connective tissue changes, in lung cancer, *July*, 22 f.
- Cor pulmonale
- in heart failure, *Dec.*, 18
- oxygen therapy in, *Dec.*, 24 f.
- Coronary artery disease
- in congestive failure, *Dec.*, 14

Coronary artery disease (*cont.*)
effect on myocardial reserve, *Dec.*,
7

Corticosterone
adrenal secretion of, *Mar.*, 8
fluorometric estimation in plasma,
Mar., 18
structure of, *Mar.*, 5

Cortisol
laboratory determinations, *Mar.*,
11, 15 ff.
metabolism, *Mar.*, 6 ff.

plasma
fluorometric estimation, *Mar.*,
18
forms and concentrations, *Mar.*,
6 f.

in lung cancer, *July*, 15
replacement therapy in congeni-
tal adrenal hyperplasia, *Mar.*,
39, 41, 42

secretion
in Cushing's syndrome, *Mar.*,
31, 32, 35
rate, *Mar.*, 6
structure of, *Mar.*, 5
synthesis defects, in adrenal hy-
perplasia, *Mar.*, 40 ff.

Cortisone, *Mar.*, 6
effects in lung cancer, *July*, 16
Coumarin, effect on vitamin K ac-
tion, *Nov.*, 31

Cushing's syndrome, *Mar.*, 31 ff.
clinical laboratory findings, *Mar.*,
33 ff.
diagnostic tests, *Mar.*, 35 ff.
with lung cancer, *July*, 13 f.
screening tests, *Mar.*, 34 f.

Cytogenetics, human, *April*, 3ff.
basic definitions, *April*, 8 ff.
normal karyotype, *April*, 12 ff.
technics of, *April*, 5 ff.

D

Dehydroepiandrosterone adrenal se-
cretion of, *Mar.*, 9

3- β -ol-Dehydrogenase deficiency, in
adrenal hyperplasia, *Mar.*, 43

Deletion, chromosomal, *April*, 15

Delirium tremens
cardiac arrest in, *Jan.*, 14
drugs in management, *Jan.*, 23,
32

magnesium deficit in, *May*, 25
physical complications of, *Jan.*,
14, 15

Dementia, in lung cancer, *July*, 27 f.
11-Deoxycortisol, determination,
Mar., 15

Depression, in alcoholic, *Jan.*, 25 ff.

Dermatitis
allergic contact, *June*, 15 ff.
diagnosis, *June*, 17 ff.
from penicillin, *June*, 22 f.
treatment, *June*, 19
atopic, differentiated from aller-
gic contact, *June*, 15 f.
from drug allergy, *June*, 14 ff.
exfoliative, from
penicillin, *June*, 27

Dermatomyositis in visceral cancer,
July, 24 f.

Desensitization
to bee extract, *June*, 40
constitutional reactions during,
June, 41 f.
dose tolerance in, *June*, 42 f.
to horse serum, *June*, 33

Dexamethasone
adrenal suppression by, *Mar.*, 29
suppression tests, *Mar.*, 36 f., 46,
47
in Cushing's syndrome, *Mar.*,
34 f.

in lung cancer, *July*, 15
in tests of adrenal insufficiency,
Mar., 29, 46, 47
therapy in virilism, *Mar.*, 45

Diabetes mellitus
adult onset, *Sept.*, 18
advances in study of, *Sept.*, 3 f.
in alcoholics, *Jan.*, 12, 16
brittle, *Sept.*, 42
effects of exercise, *Sept.*, 15
effects of oral diuretics, *Dec.*, 39
in growth period, *Sept.*, 15
juvenile, *Sept.*, 20
ketosis-prone, *Sept.*, 18 ff., 42
ketosis-resistant, *Sept.*, 18 ff., 44,
46

latent, *Sept.*, 20 f.
lipoatrophic, *Sept.*, 22
magnesium loss in severe, *May*,
26
management, *Sept.*, 29 ff.
of complications, *Sept.*, 49 f.

maintenance therapy, *Sept.*, 38 ff.
 oral hypoglycemic therapy, *Sept.*, 46 ff.
 metabolic changes in, *Sept.*, 17 ff.
 neuropathy confused with B₁₂ deficiency, *Aug.*, 18
 pathogenesis, *Sept.*, 21 ff.
 personality changes in, *Sept.*, 42
 preclinical
 clues to presence of, *Sept.*, 29
 early detection, *Sept.*, 28 f.
 and pregnancy, *Sept.*, 43
 sulfonylureas in, *Sept.*, 48
 and pregnancy, *Sept.*, 16 f., 43
 renal disease in, *Oct.*, 30 f.
 uncontrolled, *Sept.*, 30 f.
 Dialysis
 in magnesium excess, *May*, 28
 peritoneal, in progressive renal disease, *Oct.*, 37, 43
 Dibenzazepine derivatives, in alcoholism, *Jan.*, 24
 Diet
 in diabetes, *Sept.*, 38
 factor in megaloblastosis, *Aug.*, 15, 17
 in folate deficiency, *Aug.*, 37 f.
 low-sodium, in heart failure, *Dec.*, 23 f.
 Digitalis
 action on heart, *Dec.*, 27 f.
 cardiotoxic effects, *Dec.*, 29 f.
 therapy, *Dec.*, 31
 parenteral administration, *Dec.*, 35
 preparations and dosage, *Dec.*, 31 ff.
 prophylactic use, *Dec.*, 36
 Diphenylmethane compounds, in alcoholism, *Jan.*, 23 f., 30 f.
 Diploid chromosome, *April*, 8
 Disulfiram, in alcoholism management, *Jan.*, 27 f.
 Diuretics
 action of, *Dec.*, 37 f.
 for congestive failure, *Dec.*, 39 ff.
 DNA synthesis, in megaloblastic anemia, *Aug.*, 4 ff.
 Down's syndrome, *April*, 17 ff.
 Drug reactions
 allergic vs. toxic, *June*, 4 f.

analgesic-antipyretic group, *June*, 31 ff.
 anemias, *June*, 20 f.
 delayed, *June*, 11 ff.
 dermatologic, *June*, 14 ff.
 fixed drug eruption, *June*, 14
 hypersensitivity angitis, *Oct.*, 27
 local anesthetics, *June*, 34
 manifestations, *June*, 36 ff.
 unusual manifestations, *June*, 22
 see also specific drugs
 Drugs
 addictive, avoidance in treatment of alcoholism, *Jan.*, 20 f., 29
 causing chromosomal aberrations, *April*, 36 f.
 immunosuppressive, in glomerulopathies, *Oct.*, 34
 useful in alcoholism, *Jan.*, 21 ff.
 generic and trade names, *Jan.*, 32
 Drumstick, of neutrophil, *April*, 8 f., 10
 Dusts, allergic reactions to, *June*, 38
 Dyspnea, paroxysmal nocturnal: sedation in, *Dec.*, 44

E

Edema
 causes, in congestive failure, *Dec.*, 13
 pulmonary
 in congestive failure, *Dec.*, 10
 ethacrynic acid in, *Dec.*, 41
 oxygen in, *Dec.*, 25
 sedation in, *Dec.*, 44
 venesection in, *Dec.*, 42
 Effusions, pleural: in congestive failure, *Dec.*, 41 f.
 Electrocardiogram, digitalis effect, *Dec.*, 30
 Electrolyte therapy, in ketoacidosis, *Sept.*, 35 ff.
 Embolism
 amniotic fluid, *Nov.*, 34
 pulmonary, *Dec.*, 18 f.
 Emotional disturbances, and alcoholism, *Jan.*, 4 ff.
 Emphysema, pulmonary
 in alcoholics, *Jan.*, 15
 oxygen therapy in, *Dec.*, 25

Endocarditis
 bacterial
 chemoprophylaxis, *Dec.*, 44
 renal lesions, *Oct.*, 29 f., 36
 thrombotic, in lung cancer, *July*, 29
 Epinephrine
 for anaphylaxis, *June*, 9 f.
 reactions to, *June*, 34
 in serum sickness, *June*, 13
 Erythema multiforme, from drugs, *June*, 14
 Erythrocytes
 agglutination test in drug reaction, *June*, 20
 folate levels, *Aug.*, 25 f.
 magnesium levels in, *May*, 20 f.
 mean corpuscular volume, *Aug.*, 11
 in urine, measurement, *Oct.*, 36
 vitamin B₁₂ level, *Aug.*, 24, 25
 Ethacrynic acid, diuretic action, *Dec.*, 41
 Esophageal varices, in alcoholism, *Jan.*, 14
 Estradiol, structure, *Mar.*, 9
 Estrogen
 administration
 invalidating ACTH response test, *Mar.*, 35
 and steroid laboratory determination, *Mar.*, 13 f.
 adrenal secretion of, *Mar.*, 10
 excretion in lung cancer, *July*, 19
 Etiocholanolone, adrenal secretion, *Mar.*, 9
 Exercise
 cardiac output in, *Dec.*, 4 f.
 glucose utilization in, *Sept.*, 14 f.

F

Factor VII
 assay of, *Nov.*, 22 f.
 in blood clotting, *Nov.*, 9
 Fasting state, normal adaptation to, *Sept.*, 4 ff.
 Fat
 assimilation of dietary, *Sept.*, 12
 metabolism in uncontrolled diabetes, *Sept.*, 31
 unsaturated, in prophylaxis of atherosclerosis, *Sept.*, 38 f.
 see also Adipose tissue

Fibrillation, atrial: digitalis effects in, *Dec.*, 28 f.

Fibrin
 formation of, *Nov.*, 4 f.
 nature of, *Nov.*, 4
 reliquefaction of, *Nov.*, 12 f.
 stabilizing factor, *Nov.*, 5
 congenital deficiency, *Nov.*, 28 f.

Fibrinogen
 assays for, *Nov.*, 22
 catabolism of, *Nov.*, 32 f.
 causes of decreased concentration, *Nov.*, 32 ff.
 congenital deficiency, *Nov.*, 28
 conversion to fibrin, *Nov.*, 3 ff.
 plasma concentration of, *Nov.*, 33
 Fibrinogenopenia, acquired, *Nov.*, 32 ff.

Fibrinolysis
 abnormal increase in, *Nov.*, 36 f., 41
 mechanism of, *Nov.*, 12 f.
 rapid, *Nov.*, 15

Fluid balance, and magnesium depletion, *May*, 11 f.

Fluid therapy
 in cardiac failure, *Dec.*, 20
 in diabetic coma, *Sept.*, 32
 in ketoacidosis, *Sept.*, 35 f.
 magnesium requirement in, *May*, 25

Fluorescence, in plasma steroid estimation, *Mar.*, 18

Folic acid
 body stores of, *Aug.*, 25
 deficiency
 differentiated from B₁₂ deficiency, *Aug.*, 19 ff., 23 ff.
 etiologic factors, *Aug.*, 17
 folate clearance from blood in, *Aug.*, 31

 initial treatment, *Aug.*, 36 f.
 maintenance therapy, *Aug.*, 37 f.
 oral histidine load in, *Aug.*, 30 f.
 serum levels in, *Aug.*, 26
 therapeutic trial in, *Aug.*, 19 ff.
 metabolism, and vitamin B₁₂ metabolism, *Aug.*, 5 ff.

 therapy
 in severe megaloblastic anemia, *Aug.*, 32
 in uncomplicated deficiency, *Aug.*, 36 f.

Foods, allergy to, *June*, 38 f.

Formaldehyde, allergy to, *June*, 37
Fusion, chromosomal, *April*, 15

G

Gallop rhythm, in left ventricular failure, *Dec.*, 10

Gamma rays, *Feb.*, 10 f.

Gastric analysis, in megaloblastic anemia, *Aug.*, 26 f.

Gastritis, in alcoholism, *Jan.*, 14

Genitalia, external embryologic development, *April*, 26

intersexual, *April*, 27

Glomerulonephritis

acute, *Oct.*, 21 f., 34, 35

oliguric phase, *Oct.*, 13 ff.

chronic, *Oct.*, 23 f.

focal, *Oct.*, 24, 30

hereditary, *Oct.*, 24

postinfectious, *Oct.*, 21, 24, 36

subacute, *Oct.*, 22 f., 34, 36

Glomerulopathy

common forms, *Oct.*, 4 f.

defined, *Oct.*, 4, 21 ff.

pathologic physiology, *Oct.*, 12 ff.

treatment, *Oct.*, 33 ff.

Glomerulus

capillary pressure in, *Oct.*, 6 f.

filtration by, *Oct.*, 6 f.

lesions blocking, *Oct.*, 11

filtration rate

compensated decrease, *Oct.*, 16

f., 37 f.

increased, *Oct.*, 18 ff.

uncompensated decrease, *Oct.*, 12 ff., 37

structure and function, *Oct.*, 5 ff.

Glucocorticoids

effect on adrenal gland, *Mar.*, 24 f.

replacement therapy in adrenal hyperplasia, *Mar.*, 39, 41, 42

synthesis in adrenal cortex, *Mar.*, 43

Gluconeogenesis, substrates for, *Sept.*, 5

Glucose

metabolism, *Sept.*, 4 ff.

in fed state, *Sept.*, 9 ff.

therapy in ketoacidosis, *Sept.*, 36

utilization

in exercise, *Sept.*, 14 f.

in fasting, *Sept.*, 7, 9

Gold, radioactive, *Feb.*, 12

Gonadal dysgenesis, *April*, 30 ff.

Goodpasture's syndrome, *Oct.*, 29

Growth, insulin role in, *Sept.*, 15 f.

Gynecomastia, in lung cancer patients, *July*, 23

H

Hageman factor

assay of, *Nov.*, 23 f.

deficiency, *Nov.*, 17, 29

in thrombin formation, *Nov.*, 6 f.

Hageman trait, *Nov.*, 26, 29

clotting time in, *Nov.*, 17

Heart

block

complete, with congestive failure, *Dec.*, 19

digitalis-induced, *Dec.*, 30

in magnesium excess, *May*, 28 f.

oxygen therapy, *Dec.*, 25

congenital defects underlying cardiac failure, *Dec.*, 17

disease

in congestive failure, *Dec.*, 13 ff., 17 f.

rheumatic, chemoprophylaxis, *Dec.*, 43

hypertrophy, *Dec.*, 3, 8, 10

mechanical, in congestive failure, *Dec.*, 43

myocardial reserve, *Dec.*, 7

as pump, *Dec.*, 4

rate, in congestive failure, *Dec.*, 10

strain, in alcoholism, *Jan.*, 13

volume and pressure loads, *Dec.*, 4 f.

pathologic, *Dec.*, 6 f.

work load and cardiac reserve, *Dec.*, 7 f.

Heart failure

chronic, management, *Dec.*, 22 ff.

congestive

chemoprophylaxis in, *Dec.*, 43

development of, *Dec.*, 9 ff.

digitalis therapy, *Dec.*, 27 ff.

diuretics in therapy, *Dec.*, 37 ff.

fluid removal in, *Dec.*, 41 f.

Heart failure (*cont.*)

- heart disease underlying, *Dec.*, 13 ff.
- left-sided, *Dec.*, 9 f.
- patient's adjustment after, *Dec.*, 46
- prevention, *Dec.*, 46 f.
- rest in therapy, *Dec.*, 20 ff.
- right-sided, *Dec.*, 11 f.
- sedation in, *Dec.*, 44 f.
- with vitamin B₁₂ deficiency, *Aug.*, 36
- with cyanosis, oxygen therapy, *Dec.*, 24 ff.
- defined, *Dec.*, 3
- emotional aspects, *Dec.*, 45 f.
- myocardial, *Dec.*, 8
- Hemagglutination test, with penicillin, *June*, 27
- Hemophilia
 - classic, *Nov.*, 40
 - circulating anticoagulant in, *Nov.*, 35, 49
 - pattern of bleeding, *Nov.*, 27
 - transmission, *Nov.*, 25 f.
 - vascular, *Nov.*, 15, 25, 29
- Hemorrhagic disease of newborn, *Nov.*, 30
- Hemostasis
 - physiology of, *Nov.*, 3 ff.
 - platelet role in, *Nov.*, 10 f.
- Heparin
 - antithrombin action, *Nov.*, 11 f.
 - assay in plasma, *Nov.*, 24
 - endogenous, excess of, *Nov.*, 36
- Heredity
 - of diabetes, *Sept.*, 20 f.
 - in glomerulonephritis, *Oct.*, 24
- Hermaphroditism, *April*, 15 f., 26 ff.
- Heteropyknosis, *April*, 25
- Hirsutism
 - adolescent, *Mar.*, 44
 - without virilism, *Mar.*, 45 f.
- Histidine load, test of folate deficiency, *Aug.*, 30
- Hodgkin's disease, radiotherapy of, *Feb.*, 39 ff.
- Hormone
 - abnormalities, in lung cancer, *July*, 12, 13 ff.
 - of fasting, *Sept.*, 9
 - placental growth, *Sept.*, 17
 - salt-losing, *Mar.*, 41
 - tumor producing, *July*, 21

Horse serum

- desensitization, *June*, 30
- reactions to, *June*, 29 ff.
- Hydralazine, reaction to, *June*, 37
- Hydrazine derivatives, in alcoholism management, *Jan.*, 31
- Hydrocortisone, *see* Cortisol
- Hydrogen ion balance, in uremia, *Oct.*, 41 f.
- 4'-Hydroxyacetanilide, as nonallergic analgesic, *June*, 33
- 17-Hydroxycorticosteroids
 - determination
 - to evaluate cortisol production, *Mar.*, 15 f., 46
 - as screening test for Cushing's syndrome, *Mar.*, 34
 - in lung cancer, *July*, 15, 16
 - plasma, in adrenal insufficiency, *Mar.*, 27, 29, 46
- 11-Hydroxylase deficiency, in adrenal hyperplasia, *Mar.*, 42 f.
- 21-Hydroxylase deficiency, *Mar.*, 40 f., 44, 46
- 5-Hydroxytryptamine, abnormal, in bronchial adenoma, *July*, 19 f.
- Hydroxyzine, in serum sickness, *June*, 13
- Hypercalcemia
 - in lung cancer, *July*, 20 f.
 - of magnesium depletion, *May*, 8 f.
 - vitamin D effect, *May*, 20
- Hyperlipemia, carbohydrate-induced, *Sept.*, 39
- Hyperosmolar syndrome, in diabetes, *Sept.*, 30 f.
- Hyperparathyroidism, magnesium deficit in, *May*, 25 f.
- Hypersensitivity angitis, *Oct.*, 27
- Hypersensitivity reactions, *June*, 5
 - to analgesics, *June*, 31 ff.
 - to biologic products, *June*, 31 to cold, *June*, 14
 - delayed, *June*, 11 ff.
 - contact dermatitis, *June*, 15 f., 22 f.
 - hematologic, *June*, 19 ff.
 - immediate, *June*, 5 ff., 24
 - management, *June*, 8 ff.
 - immune reactions as, *June*, 22
 - to insect stings, *June*, 39 f.
 - to local anesthetics, *June*, 34

- to miscellaneous drugs, *June*, 36 ff.
- to penicillin, *June*, 22 ff.
- vs. toxic reactions, *June*, 4 f.
- Hypertension**
 - with congenital adrenal hyperplasia, *Mar.*, 39 f., 42
 - in decompensated heart disease, *Dec.*, 17
 - malignant, nephrosclerosis in, *Oct.*, 31 f., 35
- Hyperthyroidism**, with congestive failure, *Dec.*, 16
- Hypertrophy**, cardiac
 - cardiac contraction in, *Dec.*, 8
 - as compensatory mechanism, *Dec.*, 3
 - physical sign of, *Dec.*, 10
- Hypoglycemia**
 - with overinsulinization, *Sept.*, 42
 - with tolbutamide therapy, *Sept.*, 48
- Hypogonadism**, in pituitary-adrenal insufficiency, *Mar.*, 24
- Hypotension**, in delirium tremens, *Jan.*, 14
- Hypothalamus**, in abnormal regulation of ACTH, *Mar.*, 32

I

- Imipramine**, for depression, *Jan.*, 26
- Infarction**
 - acute myocardial, *Dec.*, 15
 - pituitary, *Mar.*, 23
- Infection**
 - corticoid therapy obscuring diagnosis, *Mar.*, 26
 - in insulin-treated diabetics., *Sept.*, 44
- Insect stings**, allergy to, *June*, 39 f.
- Insomnia**, in congestive failure, *Dec.*, 44
- Insulin**
 - allergic reaction to, *June*, 31
 - antagonism, *Sept.*, 22 ff.
 - effect
 - in adaptation to fasting, *Sept.*, 6 ff.
 - in fed state, *Sept.*, 9 ff.
 - in growth, *Sept.*, 15 f.

- mechanism defects, in diabetes, *Sept.*, 21 ff.
- nonantigenic, *Sept.*, 45 f.
- requirements in pregnancy, *Sept.*, 16
- resistance, *Sept.*, 22, 44 ff.
- sensitivity, *Sept.*, 41 f.
- therapy
 - during stress periods, *Sept.*, 43 f.
 - in ketoacidosis, *Sept.*, 34 f.
 - maintenance, in diabetes, *Sept.*, 40 ff.
- transport and degradation, *Sept.*, 25 f.
- Intrinsic factor**
 - assay methods, *Aug.*, 27 f.
 - circulating antibody to., *Aug.*, 29 f.
 - in therapy, *Aug.*, 35
 - in vitamin B₁₂ deficiency, *Aug.*, 16
- Iodides**, reactions to, *June*, 37
- Iodine**, radioactive, *Feb.*, 12
- Ipecac**, allergy to, *June*, 38
- Iridium**, radioactive, *Feb.*, 12
- Isochromosome**, *April*, 16
- X Turner's syndrome**, *April*, 32 f.
- Iso-dose curves**, *Feb.*, 18 ff., 23 f., 38, 41, 44, 47
- Isotopes**, radioactive
 - dilution method of steroid determination, *Mar.*, 19 f.
 - dilution test in Cushing's syndrome, *Mar.*, 35
 - in magnesium balance studies, *May*, 18
 - in radiotherapy, *Feb.*, 11 f.

J

- Jaundice**, obstructive: clotting defect in, *Nov.*, 30

K

- Karyotype**, normal human, *April*, 12 ff.
- Ketoacidosis**
 - management, *Sept.*, 34 ff.
 - pathogenesis, *Sept.*, 32 ff.
- 17-Ketogenic steroids**, *Mar.*, 17 f.
- 17-Ketosteroids**
 - from 19-carbon steroids, *Mar.*, 9 f.

- 17-Ketosteroids (*cont.*)
 in congenital adrenal hyperplasia, *Mar.*, 43, 47
 in 21-hydroxylase deficiency, *Mar.*, 40
 as measure of adrenal function, *Mar.*, 14, 28, 46
 values, with adrenal neoplasms, *Mar.*, 37
 Zimmermann reaction, *Mar.*, 11, 14, 17

- Kidney
 failure
 in glomerulonephritis, *Oct.*, 22
 in lupus nephritis, *Oct.*, 26
 magnesium excess in, *May*, 27 f.
 as filtration-reabsorption system, *Oct.*, 10
 glomerular structure and function, *Oct.*, 5 ff.
 lesion, in magnesium deficit, *May*, 13 f.
 Klinefelter's syndrome, *April*, 28 ff.

L

- Larynx carcinoma, supervoltage radiotherapy, *Feb.*, 27, 42
 Leukemia
 chromosomal aberrations from chemical agents in, *April*, 36
 chromosomal patterns in, *April*, 37 ff., 42 ff.
 chromosome number in, *April*, 38
 mimicking adrenal insufficiency, *Mar.*, 22
 Philadelphia chromosome in, *April*, 39 ff.
 Leukemoid reaction, in lung cancer, *July*, 29 f.
 Leukocytes
 alkaline phosphatase, and Ph1 chromosome, *April*, 41 f.
 effect of irradiation on, *Feb.*, 30
 of peripheral blood metaphases obtained from, *April*, 6 f.
 mitoses, *April*, 11 f.
 polymorphonuclear lobe average in megaloblastosis, *Aug.*, 12 f.
 normal lobe average, *Aug.*, 12

- Linear accelerator, *Feb.*, 14 f., 16
 isodose distribution curves, *Feb.*, 18 f.
 Lipolysis, in adipose tissue, *Sept.*, 5 f.
 Lipotropic agents, for liver damage in alcoholics, *Jan.*, 15
 Liver
 in cortisol metabolism, *Mar.*, 8
 damage, in alcoholics, *Jan.*, 15
 disease
 clotting defects in, *Nov.*, 30 f., 34
 vitamin B₁₂ levels in, *Aug.*, 25
 extract, in B₁₂ deficiency, *Aug.*, 36
 fat utilization by, *Sept.*, 12 f.
 function, adaptation to fasting, *Sept.*, 7 f.
 insulin effects in, *Sept.*, 10
 in right ventricular failure, *Dec.*, 11
 Lung carcinoma, *July*, 5 ff.
 biologic features, *July*, 8 ff.
 cell type, *July*, 10 f.
 in Cushing's syndrome, *Mar.*, 32
 diagnostic technics for screening, *July*, 7
 high-risk populations, *July*, 7
 mortality rates, *July*, 6
 radiotherapy in, *Feb.*, 45, 51
 sex difference, *July*, 11
 symptomatology and curability, *July*, 9 f.
 systemic manifestations, *July*, 11 ff.
 therapy and survival rate, *July*, 6, 10
 Lungs
 congestion in left ventricular failure, *Dec.*, 10
 necrotizing vasculitis of, *Oct.*, 29
 Lupus erythematosus
 circulating anticoagulant in, *Nov.*, 36
 renal lesion, *Oct.*, 25 f., 33, 34
 Lymphangiography, in metastatic surveys, *Feb.*, 7, 51
 Lymphoepithelioma, radiotherapy, *Feb.*, 35
 Lymphoma, malignant
 chromosome patterns, *April*, 44
 metastatic survey in, *Feb.*, 7, 51
 radiotherapy of, *Feb.*, 39 ff.

Lymphosarcoma, chromosomal abnormality in, *April*, 44

M

Macrocytosis, in diagnosis of megaloblastosis, *Aug.*, 11

Magnesium

balance studies, *May*, 16 ff.

body content of, *May*, 15, 19

deficit, *May*, 16 ff.

diseases associated with, *May*, 24 ff.

experimental, *May*, 7 ff., 12 ff.

symptoms of, *May*, 22 f.

therapy, *May*, 27

determination in serum and tissues, *May*, 6

effects on vascular system, *May*, 29

erythrocyte levels, *May*, 20 f.

excess, *May*, 27 ff.

exchangeable, average values, *May*, 19

metabolism, *May*, 15 f.

plasma values, *May*, 19

therapy, *May*, 27

evaluation of response to, *May*, 23

in parenteral fluid therapy, *May*, 25

in pregnancy toxemia, *May*, 29 f.

Malabsorption syndrome

magnesium deficit in, *May*, 24

vitamin B₁₂ absorption in, *Aug.*, 29

in vitamin B₁₂ and folate deficiency, *Aug.*, 16, 17

Malnutrition, in alcoholism, *Jan.*, 12, 15

Marfan's syndrome, *April*, 24

Megaloblastosis, *see* Anemia, megaloblastic

Meiosis, *April*, 10

nondisjunction during, *April*, 16

Mental changes, in vitamin B₁₂ deficiency, *Aug.*, 19

Mental retardation, and chromosomal abnormalities, *April*, 17 ff., 22, 24, 28, 30, 34

Mepyrapone response tests, in lung cancer, *July*, 15

Mercurial diuretics, in congestive failure, *Dec.*, 38, 39 f.

Merthiolate allergy, *June*, 37

Metabolism, cellular

adjustments to fasting, *Sept.*, 4 ff.

in fed state, *Sept.*, 9 ff.

Metals

causing contact dermatitis, *June*, 17

heavy, allergy to, *June*, 36 f.

Metaphases

methods of obtaining, *April*, 5 ff.

normal karyotype, *April*, 12 ff.

Metastases

of adrenal gland, *Mar.*, 21

cervical lymph node, management, *Feb.*, 42 ff.

survey for, *Feb.*, 7

N⁵-Methyl tetrahydrofolic acid,

in B₁₂ and folate metabolism, *Aug.*, 5, 6

in serum, *Aug.*, 25

Metirapone test, of adrenal insufficiency, *Mar.*, 29 ff., 46, 47

Mitoses, *April*, 10

multipolar, in neoplasms, *April*, 44

nondisjunction during, *April*, 16

of peripheral blood leukocytes, *April*, 11 f.

Mongolism

diagnosis, *April*, 21

mosaicism in, *April*, 21

translocation, *April*, 19 f.

trisomy 21, *April*, 17 ff.

Monosomy, *April*, 16, 19

Morphine, in congestive failure, *Dec.*, 44

Mosaicism, *April*, 16

in Klinefelter's syndrome, *April*, 29

in mongols, *April*, 21

Philadelphia chromosome after, *April*, 41

in Turner's syndrome, *April*, 33

Mucous membranes, radiation reaction in, *Feb.*, 29

Muscle

cell, adaptation to fasting, *Sept.*, 8

degenerations, in lung cancer, *July*, 25, 27

effects of magnesium deficit on, *May*, 11, 12 f., 22

Muscle (*cont.*)
 insulin effects in, *Sept.*, 11
 weakness and dermatomyositis in
 cancer, *July*, 25
 Myasthenia, in lung cancer, *July*,
 27
 Mycosis fungoides, radiotherapy of,
Feb., 50
 Myocarditis
 acute, *Dec.*, 15
 rheumatic, *Dec.*, 15
 Myocardium
 conditions decreasing reserve,
Dec., 7
 effects of magnesium deficit on,
May, 12 f.

N

Nasopharynx carcinoma, radiation
 therapy, *Feb.*, 35
 Nephritis
 lupus, *Oct.*, 25 f., 33, 34
 radiation, *Oct.*, 32
 Nephrocalcinosis, in magnesium
 deficit, *May*, 12 f.
 Nephrosclerosis, malignant, *Oct.*,
 31 f., 35
 Nephrosis, acute tubular, *Oct.*, 13 f.
 Nervous system
 central
 digitalis effects on, *Dec.*, 29
 disturbance in lung cancer,
July, 27 f.
 damage, in alcoholism, *Jan.*, 16 f.
 disorders, and carcinomas, *July*,
 25 ff.
 effect of magnesium deficit on,
May, 22 f.
 Neuritis, peripheral: in alcoholism,
Jan., 16 f.
 Neutrophils, abnormalities in meg-
 aloblastosis, *Aug.*, 13
 Nondisjunction, *April*, 16, 19, 29,
 34 f.

O

Obesity
 diabetic diet and, *Sept.*, 38, 47
 in heart patient, *Dec.*, 23
 preclinical diabetes and, *Sept.*, 28
 Oral carcinoma, radiotherapeutic
 procedures, *Feb.*, 20 ff., 33 f.

Oropharynx carcinoma, radiation
 therapy, *Feb.*, 34
 Osteoarthropathy, hypertrophic
 pulmonary: in lung cancer,
July, 19, 22 f.
 Ovary
 carcinoma, radiotherapy postop-
 eratively, *Feb.*, 35 f.
 dysgenesis, X chromosome ab-
 normalities, *April*, 33
 Oxygen
 inhalation during radiotherapy,
Feb., 52
 therapy in heart failure, *Dec.*,
 24 ff.

P

Pancreas, beta cell function in
 diabetes, *Sept.*, 26 f.
 Pancreatitis, in alcoholism, *Jan.*, 15
 Papain, allergy to, *June*, 38
 Paracentesis, in congestive failure,
Dec., 41 f.
 Paralysis
 radial nerve, in alcoholics, *Jan.*,
 17
 respiratory, in magnesium ex-
 cess, *May*, 28
 Parasites, intestinal: in vitamin
 B₁₂ deficiency, *Aug.*, 16
 Parathormone material, tumors
 producing, *July*, 21
 Parathyroid activity, in magnesium
 deficit, *May*, 8 f.
 Patau's syndrome, *April*, 23
 Penicillin
 hemagglutination test, *June*, 27
 reactions, *June*, 22 ff.
 Penicillinase, in penicillin reaction,
June, 24
 Penicilloyl-polylysine, in test for
 penicillin allergy, *June*, 25 ff.
 Peptic ulcer, in alcoholism, *Jan.*, 14
 Pericarditis
 chronic constrictive, *Dec.*, 16
 tuberculous, diagnosis, *Dec.*, 15 f.
 Personality, and alcoholism, *Jan.*,
 4 f.
 Phenformin, in diabetes, *Sept.*, 47 f.
 Phenothiazines
 in management of alcoholism,
Jan., 21 f., 30

- side effects, *Jan.*, 22
- Philadelphia chromosome, *April*, 39 ff.
- and leukocyte alkaline phosphatase, *April*, 41 f.
- Phlebectomy, bloodless: in pulmonary edema, *Dec.*, 43
- Phosphatase, alkaline: in lung cancer, *July*, 21
- Phospholipids, in thrombin formation, *Nov.*, 8, 10
- Phosphorus excretion, in magnesium deficit, *May*, 7 f., 10
- Photosensitivity
agents causing, *June*, 17
types of, *June*, 14
- Physician-patient relationship
in alcoholism, *Jan.*, 18 f.
in congestive failure, *Dec.*, 45 f.
- Phytohemagglutinin, and mitosis, *April*, 12
- Pituitary
ablation, for diabetic retinopathy, *Sept.*, 50
adrenal insufficiency, *Mar.*, 22 ff.
tests of, *Mar.*, 29 f., 46
causes of insufficiency, *Mar.*, 23 f.
tumors
in Cushing's syndrome, *Mar.*, 31, 32
radiotherapy, *Feb.*, 47 f.
- Placenta, premature separation, *Nov.*, 34
- Plants, causing contact dermatitis, *June*, 17
- Plasma
abnormal anticoagulant activity
in, *Nov.*, 15, 49
changes in magnesium depletion, *May*, 7 ff.
clotting inhibitors in, *Nov.*, 11
colloid oncotic pressure, *Oct.*, 7
cortisol forms and concentrations
in, *Mar.*, 6 f.
fibrinolysis, *Nov.*, 13
magnesium, *May*, 15, 19
steroid estimation
fluorescence in, *Mar.*, 18
sample collection for, *Mar.*, 12 f.
- thromboplastin antecedent, *Nov.*, 7, 11
assay of, *Nov.*, 23
deficiency, *Nov.*, 28
- Plasmin
actions of, *Nov.*, 12
formation of, *Nov.*, 13
inhibitors, *Nov.*, 13
- Plasminogen, in fibrinolysis, *Nov.*, 13
- Platelets
effect of irradiation on, *Feb.*, 30
role in hemostasis, *Nov.*, 10 f.
- Poison ivy dermatitis, *June*, 17, 19
- Poison oak dermatitis, *June*, 17
- Polyarteritis nodosa, renal lesions of, *Oct.*, 26 f., 34
- Polycythemia, venesection in, *Dec.*, 42
- Polymyositis, in lung cancer, *July*, 27
- Porter-Silber reaction, for cortisol-like steroids, *Mar.*, 11, 15 ff.
- Potassium
balance, in uremia, *Oct.*, 43
deficit
in ketoacidosis, *Sept.*, 36
in lung cancer, *July*, 14
in magnesium depletion, *May*, 7, 11
loss
digitalis toxicity after, *Dec.*, 31
with diuretic therapy, *Dec.*, 38
supplementary, with diuretics, *Dec.*, 38 f.
therapy, in digitalis toxicity, *Dec.*, 31
- Prediabetes, *Sept.*, 20 f.
- Prednisone, suppressive therapy in virilism, *Mar.*, 45
- Pre-eclampsia, magnesium therapy, *May*, 29 f.
- Pregnancy
metabolic changes in diabetic, *Sept.*, 16 f.
pituitary changes in, *Mar.*, 23 f.
preclinical diabetes and, *Sept.*, 43
toxemia
magnesium therapy, *May*, 29 f.
renal lesions, *Oct.*, 32 f.
- Pregnanetriol excretion, in 21-hydroxylase deficiency, *Mar.*, 40 f.
- Primrose, dermatitis from, *June*, 17
- Proaccelerin
assay of, *Nov.*, 22 f.
deficiency, *Nov.*, 25, 28
in thrombin formation, *Nov.*, 8 f.

Propanediol compounds, in alcoholism, *Jan.*, 31

Prostate carcinoma, radiotherapy, *Feb.*, 37 ff.

Proteins

as antigens in anaphylaxis, *June*, 8

insulin-antagonistic, *Sept.*, 24

Prothrombin

concentration, assay of, *Nov.*, 22

consumption test, *Nov.*, 14, 18 f., 46 f.

conversion to thrombin, *Nov.*, 5 ff.

time

one-stage, *Nov.*, 14, 19

prolonged, *Nov.*, 44

technic, *Nov.*, 44

Pseudodiploid

chromosomal pattern, *April*, 16, 19

defined, *April*, 16

Pseudohermaphroditism, *April*, 26 f.

Pulsus alternans, in ventricular failure, *Dec.*, 10

Pulsus bigeminus, digitalis-induced, *Dec.*, 30

Purpura

fibrinolytic, *Nov.*, 15, 36 f.

fulminans, *Nov.*, 35

Schönlein-Henoch's, *Oct.*, 29, 34

thrombocytopenic, *Oct.*, 28

Q

Quinidine, allergy to, *June*, 36

Quinine, allergy to, *June*, 36

R

Radiation

chromosomal aberrations due to, *April*, 35 f.

measurement, *Feb.*, 17 f.

nephritis, *Oct.*, 32

particulate, *Feb.*, 11

reactions, *Feb.*, 29 f.

sources, *Feb.*, 11 ff.

types of ionizing, *Feb.*, 10 f.

Radiation therapy

in bronchogenic cancer, *July*, 6

clinical evaluation of patient preceding, *Feb.*, 6 ff.

curative, *Feb.*, 8 ff., 31 ff.

dose measurement and dose distribution, *Feb.*, 17 ff.

future advances in, *Feb.*, 51 ff.

history of, *Feb.*, 4 f.

interstitial and intracavitary, *Feb.*, 12, 20 ff.

palliative, *Feb.*, 10, 45, 46

supervoltage, *Feb.*, 13 ff.

beam alignment, *Feb.*, 26 ff.

results, *Feb.*, 31 ff.

treatment planning, *Feb.*, 23 f.

treatment schedule, *Feb.*, 28

technics, *Feb.*, 10 ff.

Radiography

for localization, in supervoltage therapy, *Feb.*, 25 f.

for positioning of radiation sources, *Feb.*, 20 ff.

reactions to contrast mediums, *June*, 35 f.

technics for adrenal tumor, *Mar.*, 37

Radium

interstitial and intracavitary therapy, *Feb.*, 12, 20 ff.

radiations from, *Feb.*, 11 f.

Ragweed dermatitis, *June*, 17, 19

Reserpine, in alcoholism treatment, *Jan.*, 30

Resins, causing contact dermatitis, *June*, 17

Respiration, artificial: in anaphylactic shock, *June*, 9

Retinoblastoma, radiotherapy, *Feb.*, 48 ff.

Retinopathy, diabetic, *Sept.*, 50 f.

RNA synthesis, in megaloblastic anemia, *Aug.*, 4 ff.

S

Salt wasting

in congenital adrenal hyperplasia, *Mar.*, 39

See also Sodium

Satellite, chromosome, *April*, 11

enlarged, *April*, 24

Schilling test, of vitamin B₁₂ absorption, *Aug.*, 28

Schönlein-Henoch's purpura, *Oct.*, 29, 34

Scleroderma, renal lesion, *Oct.*, 28, 34

- Sedation, in congestive failure, *Dec.*, 44
- Seminomas, radiotherapy results, *Feb.*, 36 f.
- Serum
 immediate allergic reactions to, *June*, 29
 sickness, *June*, 11 ff.
 due to bee sting, *June*, 40
 from horse serum, *June*, 29 ff.
 penicillin, *June*, 23 ff.
 treatment, *June*, 13, 24
- Sex
 chromatin, *April*, 8, 10, 25
 embryonic formation of genitalia, *April*, 26
 genetic determination, *April*, 25 f.
 hormone control of, *April*, 26
 misdiagnosis, in congenital adrenal hyperplasia, *Mar.*, 39
- Sex chromosome patterns, *April*, 25
 in hermaphroditism, *April*, 27
 in Klinefelter's syndrome, *April*, 28 ff.
 triple X, *April*, 34 f.
 in Turner's syndrome, *April*, 31, 33 f.
 XO, *April*, 31 f.
 Xx, *April*, 32
 XX/XO/Xx, *April*, 33 f.
 XXY, *April*, 28 f.
 XXXY, *April*, 29 f.
- Sheehan's syndrome, *Mar.*, 23
- Shock
 anaphylactic, *June*, 7
 relation to adrenal insufficiency, *Mar.*, 25 f.
- Sinuses, paranasal: supravoltage radiotherapy for carcinoma, *Feb.*, 24, 41 f.
- Skin
 abnormalities, in lung cancer, *July*, 23 ff.
 changes, in magnesium depletion, *May*, 7
 hypersensitivity reactions, *June*, 6, 13 ff.
 metaphases from, technic, *April*, 7 f.
 radiation reaction in, *Feb.*, 29 f.
- Skin tests
 with aspirin, *June*, 33
 in bee sting allergy, *June*, 40
 intradermal, *June*, 19, 25
- antigens contraindicated, *June*, 41
 with horse serum, *June*, 29
 systemic reactions to, *June*, 40, 41
- passive transfer, in penicillin allergy, *June*, 25
- patch, for contact allergy, *June*, 18 f.
- in penicillin allergy, *June*, 23, 24 ff.
 with penicilloylol-polylysine, *June*, 25 ff.
- scratch
 with horse serum, *June*, 29
 reactions to, *June*, 41
- Snake bite, defibrination from, *Nov.*, 34
- Sodium
 balance
 in acute glomerulitides, *Oct.*, 14 ff., 37
 in normal kidney, *Oct.*, 39
 in progressive renal disease, *Oct.*, 18 ff., 38 ff.
- deficit
 in ketoacidosis, *Sept.*, 36
 in lung cancer, *July*, 17 f.
- excretion range in uremic patient, *Oct.*, 40
- filtration-reabsorption of, *Oct.*, 10 f.
- loss
 in adrenal hyperplasia, *Mar.*, 39, 41
 physiologic mechanism, *Mar.*, 41 f.
- restriction in heart failure, *Dec.*, 23 f.
- retention, in congestive failure, *Dec.*, 11 f.
- Somogyi effect, in insulin therapy, *Sept.*, 42 f.
- Spironolactone, in congestive failure, *Dec.*, 40
- Starling's law, *Dec.*, 9
- Steroids
 adrenal cortex
 estimation of production rates, *Mar.*, 20
 isotope dilution in determination, *Mar.*, 19 f.
 laboratory determinations, *Mar.*, 10 ff.

Steroids (*cont.*)
 normal, *Mar.*, 4 ff.
 structure and metabolism,
Mar., 4 ff.
 17-ketogenic, *Mar.*, 17 f.
 studies in adrenal disease, *Mar.*,
 27 f., 46
 Steroid therapy
 in acute allergic reactions, *June*,
 10
 in acute rheumatic carditis, *Dec.*,
 15
 anabolic, for diabetic retin-
 opathy, *Sept.*, 51
 in contact dermatitis, *June*, 19
 effect on adrenal gland, *Mar.*, 24
 effect on steroid determinations,
Mar., 13
 in hypersensitivity angitis, *Oct.*,
 27, 34
 in lupus nephritis, *Oct.*, 33, 36
 in polyarteritis nodosa, *Oct.*, 34,
 36
 in Schönlein-Henoch's purpura,
Oct., 34
 Stokes-Adams syndrome, *Dec.*, 19
 Streptomycin, allergic reactions to,
June, 27 f.
 Stress
 and adrenal insufficiency, *Mar.*,
 25
 increased fibrinolysis in, *Nov.*, 37
 in insulin-treated diabetics, *Sept.*,
 43
 Stuart factor
 assay of, *Nov.*, 22 f.
 in thrombin formation, *Nov.*, 8 f.
 Sturge-Weber syndrome, *April*, 24 f.
 Suicide, in alcoholic patients, *Jan.*,
 5, 25
 Sulfonamides, allergy to, *June*, 28
 Sulfonylureas, in diabetes, *Sept.*,
 47 ff.
 Synalbumin, as insulin antagonist,
Sept., 24 f.

T

Tachycardia
 in alcoholism, *Jan.*, 13 f.
 sinus, treatment, *Dec.*, 20
 Teletherapy, *Feb.*, 12, 13, 23 ff.

Teratocarcinoma, radiotherapy re-
 sults, *Feb.*, 36 f.
 Testes
 radiotherapy of malignant tu-
 mors, *Feb.*, 36 f.
 Testosterone
 adrenal secretion, *Mar.*, 9 f.
 glucuronide, in virilism syn-
 drome, *Mar.*, 45
 structure, *Mar.*, 9
 Tetany, and magnesium deficit,
May, 22
 Tetraploid, *April*, 17
 Thiamine deficiency, in cardiac fail-
 ure, *Dec.*, 16 f.
 Thiazides, in congestive failure,
Dec., 39 f.
 6-Thioguanine, in glomerulopa-
 thies, *Oct.*, 34 f.
 Thoracentesis, in congestive failure,
Dec., 41 f.
 Thorn test, for adrenal insufficiency,
Mar., 27
 Thrombin
 in fibrin formation, *Nov.*, 4 f.
 formation, *Nov.*, 5 ff.
 extrinsic pathway, *Nov.*, 8 f.
 intrinsic pathway, *Nov.*, 6 ff.
 inhibiting mechanisms, *Nov.*, 11
 time, *Nov.*, 24
 prolonged, *Nov.*, 42 f.
 Thrombocytopenia
 clotting defects in, *Nov.*, 15, 19
 from drugs, *June*, 20 f.
 Thromboembolism, prevention in
 cardiac failure, *Dec.*, 21 f.
 Thromboplastin
 antecedent, *Nov.*, 7, 11
 generation test, *Nov.*, 15, 20 ff.,
 48
 time (partial), *Nov.*, 14, 18
 tissue, *Nov.*, 6, 8 f.
 Thrombosis, venous
 in cancer, *July*, 28 f.
 in congestive failure, *Dec.*, 18
 Tolbutamide, in diabetes, *Sept.*,
 47 ff.
 Tongue carcinoma
 interstitial radiotherapy, *Feb.*,
 20 f., 33
 supravoltage therapy, *Feb.*, 33 f.
 Transcortin, *Mar.*, 6
 Translocation
 of chromosomes, *April*, 15, 17,

19, 38, 41
 in mongolism, *April*, 19 ff.
 Triamterine, in congestive failure,
Dec., 41
 Trisomy, *April*, 16, 17, 25
 D syndrome, *April*, 23
 E syndrome, *April*, 22
 21 mongolism, *April*, 17 ff.
 Tuberculosis
 adrenal destruction by, *Mar.*,
 20 f.
 in alcoholics, *Jan.*, 16
 pericardial, *Dec.*, 15 f.
 Tumor board, hospital, *Feb.*, 6
 Tumors
 adrenal, radiologic technics in,
Mar., 37
 chromosome abnormalities in,
April, 44 f.
 pituitary
 causing insufficiency, *Mar.*, 23
 in Cushing's syndrome, *Mar.*,
 31, 32
 Turner's syndrome, *April*, 30 ff.
 chromosomal abnormalities,
April, 31 ff.
 male, *April*, 34

U

Uremia
 hydrogen ion balance in, *Oct.*,
 41 f.
 salt and water balance in, *Oct.*,
 39 ff.
 Urine
 abnormalities
 with decreased GFR, *Oct.*, 13 ff.
 in glomerulonephritis, *Oct.*, 21
 f., 23
 in lupus nephritis, *Oct.*, 26
 collection of specimens for ste-
 roid determination, *Mar.*, 11
 f.
 measure of red cells in, *Oct.*, 36
 Urticaria
 from aspirin allergy, *June*, 31 f.
 generalized, in anaphylaxis,
June, 6
 Uterus: cramping, in anaphylaxis,
June, 7

V

Valsalva maneuver, in left ventric-
 ular failure, *Dec.*, 12
 Van de Graaff generator, *Feb.*, 13,
 14
 Varices, esophageal: in alcoholism,
Jan., 14
 Venesection, in heart failure, *Dec.*,
 42 f.
 Virilism syndromes, from adrenal
 abnormalities, *Mar.*, 38 f.,
 44 f.
 Vitamin B₁₂
 body storage of, *Aug.*, 24
 deficiency
 complications of, *Aug.*, 36
 differentiated from folate de-
 ficiency, *Aug.*, 19 ff., 23 ff.
 and DNA synthesis, *Aug.*, 6 f.
 etiologic factors, *Aug.*, 15 f.
 neurologic damage in, *Aug.*, 18
 f., 34
 serum levels in, *Aug.*, 24, 26
 therapeutic trial in, *Aug.*, 19
 ff.
 treatment, *Aug.*, 33 f.
 metabolism, interrelation with
 folate metabolism, *Aug.*, 5 ff.
 therapy
 choice of preparation, *Aug.*, 34
 f.
 maintenance, *Aug.*, 33 ff.
 in severe megaloblastic an-
 emia, *Aug.*, 32
 Vitamin D
 effect on serum magnesium, *May*,
 20
 and hypomagnesemia, *May*, 19 f.,
 26
 Vitamin K
 absorption and utilization, *Nov.*,
 30
 -dependent clotting factors, *Nov.*,
 29 f., 44 f.
 Vitamins, in treatment of alcohol-
 ism, *Jan.*, 13, 17, 31
 Vomiting, phenothiazines to con-
 trol, *Jan.*, 21 f.
 Water
 intoxication, with salt depletion,
July, 17 f.

Water (*cont.*)
test, in adrenal insufficiency,
Mar., 27
von Willebrand's disease, bleeding
time in, Nov., 15

X

X chromosome, April, 25
inactivated, April, 25
isochromosome X, April, 32
in normal karyotype, April, 15
triple, April, 34 f.
See also Sex chromosome pat-
terns
X-rays, Feb., 10 f.
apparatus

kilovoltage energy range, Feb.,
12 f.
superficial therapy, Feb., 12 f.
supervoltage and megavoltage
energy range, Feb., 13 ff.
dose measurement, Feb., 18 ff.

Y

Y chromosome, in normal karyo-
type, April, 14 f.

Z

Zimmermann reaction, for 17-keto-
steroids, Mar., 11, 14, 17

